Interestingly, in xenograft models of pancreatic cancer, the combination of gemcitabine and EGFR-targeted therapy significantly inhibited the metastatic process and resulted in improved overall survival (12,13). The gene discussed is EGFR; the disease is familial pancreatic carcinoma.